

Christopher M Booth

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/3043271/publications.pdf>

Version: 2024-02-01

202
papers

7,274
citations

76326
40
h-index

66911
78
g-index

203
all docs

203
docs citations

203
times ranked

10575
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area. JAMA - Journal of the American Medical Association, 2003, 289, 2801.	7.4	1,188
2	Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ, The, 2020, 371, m4087.	6.0	606
3	Is This Patient Dead, Vegetative, or Severely Neurologically Impaired?. JAMA - Journal of the American Medical Association, 2004, 291, 870.	7.4	454
4	Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nature Reviews Clinical Oncology, 2020, 17, 268-270.	27.6	333
5	The impact of socioeconomic status on stage of cancer at diagnosis and survival. Cancer, 2010, 116, 4160-4167.	4.1	244
6	Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 54 Clinical Oncology, 2016, 34, 1945-1952.	1.6	202
7	Gastrointestinal promotility drugs in the critical care setting: A systematic review of the evidence*. Critical Care Medicine, 2002, 30, 1429-1435.	0.9	198
8	Real-world data: towards achieving the achievable in cancer care. Nature Reviews Clinical Oncology, 2019, 16, 312-325.	27.6	187
9	Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncology, The, 2017, 18, 887-894.	10.7	108
10	The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2016, 160, 17-28.	2.5	102
11	Priorities for cancer research in low- and middle-income countries: a global perspective. Nature Medicine, 2022, 28, 649-657.	30.7	101
12	Cervical cancer screening and HPV vaccine acceptability among rural and urban women in Kilimanjaro Region, Tanzania. BMJ Open, 2015, 5, e005828-e005828.	1.9	98
13	Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. JAMA Oncology, 2021, 7, 728.	7.1	94
14	Cancer in sub-Saharan Africa: a Lancet Oncology Commission. Lancet Oncology, The, 2022, 23, e251-e312.	10.7	94
15	Perioperative chemotherapy for muscleâ€invasive bladder cancer: A populationâ€based outcomes study. Cancer, 2014, 120, 1630-1638.	4.1	83
16	An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries. JAMA Oncology, 2021, 7, 379.	7.1	81
17	The Time Toxicity of Cancer Treatment. Journal of Clinical Oncology, 2022, 40, 1611-1615.	1.6	77
18	Relevance of randomised controlled trials in oncology. Lancet Oncology, The, 2016, 17, e560-e567.	10.7	74

#	ARTICLE	IF	CITATIONS
19	Association Between Prognosis and Tumor Laterality in Early-Stage Colon Cancer. JAMA Oncology, 2017, 3, 1386.	7.1	73
20	Translating New Medical Therapies Into Societal Benefit. JAMA - Journal of the American Medical Association, 2008, 300, 2177.	7.4	71
21	Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. Journal of the National Cancer Institute, 2018, 110, 486-492.	6.3	70
22	Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncology, The, 2021, 22, 1367-1377.	10.7	69
23	Recommendations for Surgery During the Novel Coronavirus (COVID-19) Epidemic. Indian Journal of Surgery, 2020, 82, 124-128.	0.3	67
24	Management and Outcome of Colorectal Cancer Liver Metastases in Elderly Patients. JAMA Oncology, 2015, 1, 1111.	7.1	65
25	Adoption of Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Population-Based Outcomes Study. Journal of Clinical Oncology, 2010, 28, 3472-3478.	1.6	62
26	Severe acute respiratory syndrome and critical care medicine: The Toronto experience. Critical Care Medicine, 2005, 33, S53-S60.	0.9	60
27	Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder cancer: systematic review and meta-analysis. BJU International, 2018, 122, 744-753.	2.5	60
28	Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. The Lancet Gastroenterology and Hepatology, 2019, 4, 217-226.	8.1	59
29	Time to adjuvant chemotherapy and survival in non-small cell lung cancer. Cancer, 2013, 119, 1243-1250.	4.1	52
30	A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain Imaging and Behavior, 2019, 13, 15-26.	2.1	51
31	Use and Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer: A Population-Based Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 47-56.	4.9	50
32	Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap. Journal of Clinical Oncology, 2020, 38, 1651-1654.	1.6	50
33	Disease Characteristics, Clinical Management, and Outcomes of Young Patients With Colon Cancer: A Population-based Study. Clinical Colorectal Cancer, 2018, 17, e651-e661.	2.3	49
34	Choosing Wisely India: ten low-value or harmful practices that should be avoided in cancer care. Lancet Oncology, The, 2019, 20, e218-e223.	10.7	47
35	Processes of Care and the Impact of Surgical Volumes on Cancer-specific Survival: A Population-based Study in Bladder Cancer. Urology, 2014, 84, 1049-1057.	1.0	46
36	Radical Cystectomy and Adjuvant Chemotherapy for Bladder Cancer in the Elderly: A Population-based Study. Urology, 2015, 85, 791-798.	1.0	46

#	ARTICLE	IF	CITATIONS
37	Outcomes of squamous histology in bladder cancer: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 425.e7-425.e13.	1.6	45
38	Perioperative chemotherapy for bladder cancer in the general population: Are practice patterns finally changing?. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 89.e13-89.e20.	1.6	45
39	Use of Preoperative Magnetic Resonance Imaging for Breast Cancer. JAMA Oncology, 2015, 1, 1238.	7.1	43
40	Palliative Care is Associated with Reduced Aggressive End-of-Life Care in Patients with Gastrointestinal Cancer. Annals of Surgical Oncology, 2018, 25, 1478-1487.	1.5	43
41	Increased incidence but improved median overall survival for biliary tract cancers diagnosed in Ontario from 1994 through 2012: A population-based study. Cancer, 2016, 122, 2534-2543.	4.1	38
42	Temporal trends in the association between socioeconomic status and cancer survival in Ontario: a population-based retrospective study. CMAJ Open, 2017, 5, E682-E689.	2.4	37
43	PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis. Cancer Treatment Reviews, 2019, 76, 51-56.	7.7	36
44	Communication in the Toronto critical care community: important lessons learned during SARS. Critical Care, 2003, 7, 405.	5.8	35
45	Cancer care workforce in Africa: perspectives from a global survey. Infectious Agents and Cancer, 2019, 14, 11.	2.6	34
46	Approvals in 2016: questioning the clinical benefit of anticancer therapies. Nature Reviews Clinical Oncology, 2017, 14, 135-136.	27.6	33
47	Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice. European Journal of Cancer, 2014, 50, 2303-2308.	2.8	32
48	Delivery of Global Cancer Care: An International Study of Medical Oncology Workload. Journal of Global Oncology, 2018, , 1-11.	0.5	32
49	Palliative Care and Symptom Burden in the Last Year of Life: A Population-Based Study of Patients with Gastrointestinal Cancer. Annals of Surgical Oncology, 2019, 26, 2336-2345.	1.5	32
50	Undisclosed financial conflicts of interest among authors of American Society of Clinical Oncology clinical practice guidelines. Cancer, 2019, 125, 4069-4075.	4.1	30
51	Patterns of referral for perioperative chemotherapy among patients with muscle-invasive bladder cancer: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1200-1208.	1.6	29
52	Reasons for Delay in Time to Initiation of Adjuvant Chemotherapy for Colon Cancer. Journal of Oncology Practice, 2015, 11, e28-e35.	2.5	28
53	Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials. JAMA Oncology, 2018, 4, 1610.	7.1	27
54	Perioperative chemotherapy for urothelial carcinoma of the upper urinary tract: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2018, 128, 58-64.	4.4	27

#	ARTICLE	IF	CITATIONS
55	Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 397-404.e1.	2.3	26
56	The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer. <i>JAMA Oncology</i> , 2019, 5, 1779.	7.1	26
57	Overview of Delivery of Cancer Care in Nepal: Current Status and Future Priorities. <i>JCO Global Oncology</i> , 2020, 6, 1211-1217.	1.8	26
58	Adjuvant Chemotherapy for Non-small Cell Lung Cancer: Practice Patterns and Outcomes in the General Population of Ontario, Canada. <i>Journal of Thoracic Oncology</i> , 2012, 7, 559-566.	1.1	25
59	Disease-free survival as an end-point in the treatment of solid tumours â€” Perspectives from clinical trials and clinical practice. <i>European Journal of Cancer</i> , 2014, 50, 2298-2302.	2.8	25
60	The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research. <i>Lancet Oncology</i> , The, 2021, 22, e369-e376.	10.7	25
61	Biased Evaluation in Cancer Drug Trialsâ€”How Use of Progression-Free Survival as the Primary End Point Can Mislead. <i>JAMA Oncology</i> , 2022, 8, 679.	7.1	25
62	Management of stage <sc>III</sc> colon cancer in the elderly: Practice patterns and outcomes in the general population. <i>Cancer</i> , 2017, 123, 2840-2849.	4.1	24
63	Cancer groundshot: going global before going to the moon. <i>Lancet Oncology</i> , The, 2018, 19, 288-290.	10.7	24
64	Real-world evidence and regulatory drug approval. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 271-272.	27.6	24
65	Progression-free survival: it is time for a new name. <i>Lancet Oncology</i> , The, 2022, 23, 328-330.	10.7	24
66	Risk factors and timing of venous thromboembolism after radical cystectomy in routine clinical practice: a populationâ€”based study. <i>BJU International</i> , 2016, 118, 714-722.	2.5	23
67	Peri-operative allogeneic blood transfusion and outcomes after radical cystectomy: a population-based study. <i>World Journal of Urology</i> , 2017, 35, 1435-1442.	2.2	23
68	State of Cancer Control in Rwanda: Past, Present, and Future Opportunities. <i>JCO Global Oncology</i> , 2020, 6, 1171-1177.	1.8	23
69	The Final 30 Days of Life. <i>Journal of Palliative Care</i> , 2017, 32, 92-100.	1.0	22
70	Is there a gender effect in bladder cancer? A population-based study of practice and outcomes. <i>Canadian Urological Association Journal</i> , 2015, 9, 269.	0.6	21
71	Lymph node counts are valid indicators of the quality of surgical care in bladder cancer: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 425.e15-425.e23.	1.6	21
72	Pulmonary Metastasectomy for Colorectal Cancer: Predictors of Survival in Routine Surgical Practice. <i>Annals of Thoracic Surgery</i> , 2018, 105, 1605-1612.	1.3	21

#	ARTICLE	IF	CITATIONS
73	Factors Associated With Chemoradiation Therapy Interruption and Noncompletion Among Patients With Squamous Cell Anal Carcinoma. JAMA Oncology, 2020, 6, 881.	7.1	21
74	Cancer Risk and Mortality in Patients With Kidney Disease: A Population-Based Cohort Study. American Journal of Kidney Diseases, 2022, 80, 436-448.e1.	1.9	21
75	Temporal trends in management and outcomes of testicular cancer: A population-based study. Cancer, 2018, 124, 2724-2732.	4.1	20
76	Delivery of cancer care in Sri Lanka. Journal of Cancer Policy, 2018, 18, 20-24.	1.4	20
77	Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer. JAMA Oncology, 2020, 6, 1751.	7.1	20
78	Simultaneous resection of primary colorectal cancer and synchronous liver metastases: a population-based study. Canadian Journal of Surgery, 2017, 60, 122-128.	1.2	20
79	Is there a measurable association of epidural use at cystectomy and postoperative outcomes? A population-based study. Canadian Urological Association Journal, 2016, 10, 321.	0.6	19
80	Outcomes after repeat hepatic resection for recurrent metastatic colorectal cancer: A population-based study. American Journal of Surgery, 2017, 213, 1053-1059.	1.8	19
81	Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 374-387.	3.8	19
82	Rotation to Methadone After Opioid Dose Escalation. Journal of Pain and Palliative Care Pharmacotherapy, 2005, 19, 25-31.	0.8	17
83	Outcomes of Resected Colorectal Cancer Lung Metastases in Routine Clinical Practice: A Population-Based Study. Annals of Surgical Oncology, 2016, 23, 1057-1063.	1.5	17
84	Has the Current Oncology Value Paradigm Forgotten Patients' Time?. JAMA Oncology, 2021, 7, 1757.	7.1	17
85	Medical oncology in India: Workload, infrastructure, and delivery of care. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 121-127.	0.2	16
86	Prioritising locations for radiotherapy equipment in Brazil: a cross-sectional, population-based study and development of a LINAC shortage index. Lancet Oncology, The, 2022, 23, 531-539.	10.7	16
87	Why is perioperative chemotherapy for bladder cancer underutilized?. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 391-395.	1.6	15
88	Peri-operative blood transfusion for resected colon cancer: Practice patterns and outcomes in a population-based study. Cancer Epidemiology, 2017, 51, 35-40.	1.9	15
89	Medical oncology job satisfaction: Results of a global survey. Seminars in Oncology, 2019, 46, 73-82.	2.2	15
90	Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study. Journal of Clinical Oncology, 2021, 39, 779-786.	1.6	15

#	ARTICLE	IF	CITATIONS
91	A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 124-129.	1.9	14
92	Setting Quality Improvement Priorities for Women Receiving Systemic Therapy for Early-Stage Breast Cancer by Using Population-Level Administrative Data. <i>Journal of Clinical Oncology</i> , 2017, 35, 3207-3214.	1.6	14
93	Sociodemographic Factors and Stage of Cancer at Diagnosis: A Population-Based Study in South India. <i>Journal of Global Oncology</i> , 2019, 5, 1-10.	0.5	14
94	Symptom Evolution in Patients with Esophageal and Gastric Cancer Receiving Palliative Chemotherapy: A Population-Based Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 79-87.	1.5	14
95	Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. <i>JAMA Internal Medicine</i> , 2021, 181, 1596-1604.	5.1	14
96	Adjuvant chemotherapy for resected non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2006, 1, 180-7.	1.1	14
97	Cancer treatments should benefit patients: a common-sense revolution in oncology. <i>Nature Medicine</i> , 2022, 28, 617-620.	30.7	14
98	Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class. <i>JAMA Oncology</i> , 2022, 8, 879.	7.1	14
99	Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study. <i>Bladder Cancer</i> , 2018, 4, 419-428.	0.4	13
100	Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians?. <i>JCO Oncology Practice</i> , 2022, 18, e1164-e1169.	2.9	13
101	Benefits of Adjuvant Chemotherapy for Bladder Cancer. <i>JAMA Oncology</i> , 2015, 1, 727.	7.1	12
102	Utilisation of preoperative imaging for muscle-invasive bladder cancer: a population-based study. <i>BJU International</i> , 2016, 117, 430-438.	2.5	12
103	Choosing Wisely for COVID-19: ten evidence-based recommendations for patients and physicians. <i>Nature Medicine</i> , 2021, 27, 1324-1327.	30.7	12
104	Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of <i>ERBB2</i> -Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, e212140.	7.1	12
105	Documenting Goals of Care Among Patients With Advanced Cancer: Results of a Quality Improvement Initiative. <i>Journal of Oncology Practice</i> , 2018, 14, e557-e565.	2.5	11
106	Impact of Concomitant Chemotherapy on Outcomes of Radiation Therapy for Head-and-Neck Cancer: A Population-Based Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 115-121.	0.8	10
107	Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e535-e541.	1.9	10
108	Concurrent chemoradiotherapy for bladder cancer: Practice patterns and outcomes in the general population. <i>Radiotherapy and Oncology</i> , 2018, 127, 136-142.	0.6	10

#	ARTICLE	IF	CITATIONS
109	Incidence, Timing, and Outcomes of Venous Thromboembolism in Patients Undergoing Surgery for Esophagogastric Cancer: A Population-Based Cohort Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 4393-4404.	1.5	10
110	Establishing achievable benchmarks for quality improvement in systemic therapy for early-stage breast cancer. <i>Cancer</i> , 2017, 123, 3772-3780.	4.1	9
111	Neoadjuvant chemotherapy for muscle-invasive bladder cancer: Underused across the 49th parallel. <i>Canadian Urological Association Journal</i> , 2018, 13, 29-31.	0.6	9
112	Multiplicity in oncology randomised controlled trials: a threat to medical evidence?. <i>Lancet Oncology</i> , The, 2019, 20, 1638-1640.	10.7	9
113	Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?. <i>European Urology</i> , 2021, 79, 710-712.	1.9	9
114	Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study. <i>Cancer</i> , 2022, 128, 311-316.	4.1	9
115	Pathological factors associated with survival benefit from adjuvant chemotherapy (<scp>ACT</scp>): a population-based study of bladder cancer. <i>BJU International</i> , 2015, 116, 373-381.	2.5	8
116	Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers. <i>Bladder Cancer</i> , 2018, 4, 49-65.	0.4	8
117	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. <i>Canadian Urological Association Journal</i> , 2019, 13, 318-327.	0.6	8
118	Educational Status, Cancer Stage, and Survival in South India: A Population-Based Study. <i>JCO Global Oncology</i> , 2020, 6, 1704-1711.	1.8	8
119	Trimodality Therapy for Muscle-Invasive Bladder Cancer: Concurrent Chemotherapy is Not Enough. <i>Journal of Clinical Oncology</i> , 2020, 38, 2709-2711.	1.6	8
120	Perioperative Chemotherapy for Resectable Liver Metastases in Colorectal Cancer: Do We Have a Blind Spot?. <i>Journal of Clinical Oncology</i> , 2021, 39, 3767-3769.	1.6	8
121	Delivery of Adjuvant Oxaliplatin for Colon Cancer: Insights From Routine Clinical Practice. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1548-1554.	4.9	7
122	Patterns of Referral for Adjuvant Chemotherapy for Stage II and III Colon Cancer: A Population-Based Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 2529-2538.	1.5	7
123	Bladder-sparing radiotherapy for muscle-invasive bladder cancer: A survey of providers to determine barriers and enablers. <i>Radiotherapy and Oncology</i> , 2017, 125, 351-356.	0.6	7
124	Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research Groups. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky050.	2.9	7
125	From the \$80 hamburger to managing conflicts of interest with the pharmaceutical industry. <i>BMJ: British Medical Journal</i> , 2019, 365, l1939.	2.3	7
126	Do doctors who order more routine medical tests diagnose more cancers? A population-based study from Ontario Canada. <i>Cancer Medicine</i> , 2019, 8, 850-859.	2.8	7

#	ARTICLE	IF	CITATIONS
127	Demographic, tumour, and treatment characteristics of female patients with breast cancer in Sri Lanka; results from a hospital-based cancer registry. BMC Cancer, 2021, 21, 1175.	2.6	7
128	Impact of the COVID-19 Pandemic on Cancer Researchers in 2020: A Qualitative Study of Events to Inform Mitigation Strategies. Frontiers in Public Health, 2021, 9, 741223.	2.7	7
129	Delivery of Pediatric Cancer Care in Mexico: A National Survey. Journal of Global Oncology, 2018, 4, 1-12.	0.5	6
130	Estimating the optimal perioperative chemotherapy utilization rate for muscle-invasive bladder cancer. Cancer Medicine, 2019, 8, 6258-6271.	2.8	6
131	First-Line Palliative Chemotherapy for Esophageal and Gastric Cancer: Practice Patterns and Outcomes in the General Population. JCO Oncology Practice, 2021, 17, e1537-e1550.	2.9	6
132	Perioperative blood transfusion and resection of colorectal cancer liver metastases: outcomes in routine clinical practice. Hpb, 2021, 23, 404-412.	0.3	6
133	Risk of COVID-19 in Patients With Cancer. JAMA Oncology, 2020, 6, 1471.	7.1	5
134	Industry payments to US physicians for cancer therapeutics: An analysis of the 2016-2018 open payments datasets. Journal of Cancer Policy, 2021, 28, 100283.	1.4	5
135	Improving access and quality of palliative care in Kerala: A cross-sectional study of providers in routine practice. Indian Journal of Palliative Care, 2020, 26, 500.	1.0	5
136	Use of Palliative Chemotherapy for Advanced Bladder Cancer: Patterns of Care in Routine Clinical Practice. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 291-298.	4.9	4
137	Utilization of preoperative imaging for colon cancer: A population-based study. Journal of Surgical Oncology, 2017, 115, 202-207.	1.7	4
138	Benchmarking our urological care: It's just the beginning. Canadian Urological Association Journal, 2017, 11, 223-4.	0.6	4
139	Use of radiotherapy for bladder cancer: A population-based study of evolving referral and practice patterns. Canadian Urological Association Journal, 2018, 13, 92-101.	0.6	4
140	Why patients receive treatments that are minimally effective?. Nature Reviews Clinical Oncology, 2019, 16, 3-4.	27.6	4
141	Controversies in the management of clinical stage 1 testis cancer. Canadian Urological Association Journal, 2020, 14, E537-E542.	0.6	4
142	“Choosing Wisely” for Cancer Care in India. Indian Journal of Surgical Oncology, 2020, 11, 4-6.	0.7	4
143	Childhood cancer care: closing equity gaps on the ground. Lancet Oncology, The, 2020, 21, 485-487.	10.7	4
144	Utilization of imaging for active surveillance in testicular cancer: Is real-world practice concordant with guidelines?. Canadian Urological Association Journal, 2021, 16, .	0.6	4

#	ARTICLE	IF	CITATIONS
145	Incidence and Risk Factors of Venous Thromboembolism Following Hepatectomy for Colorectal Metastases: A Population-Based Retrospective Cohort Study. World Journal of Surgery, 2022, 46, 180-188.	1.6	4
146	Training of oncologists: results of a global survey. Ecancermedicalsecience, 2020, 14, 1074.	1.1	4
147	Delivering high-quality care to patients with muscle-invasive bladder cancer: Insights from routine practice in Ontario. Canadian Urological Association Journal, 2014, 8, 297.	0.6	3
148	Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer. Cancer Medicine, 2019, 8, 5590-5599.	2.8	3
149	Delivery of chemotherapy for testicular cancer in routine practice: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 183.e17-183.e24.	1.6	3
150	Histology at transurethral resection of bladder tumor and radical cystectomy for bladder cancer: Insights from population-based data. Canadian Urological Association Journal, 2020, 15, 138-140.	0.6	3
151	Clinical Oncology Workload in Sri Lanka: Infrastructure, Supports, and Delivery of Clinical Care. JCO Global Oncology, 2021, 7, 1703-1710.	1.8	3
152	Stage III NSCLC “is it time to centralize care?”. Nature Reviews Clinical Oncology, 2016, 13, 657-658.	27.6	2
153	Value of Biomarker Expression for Randomized Clinical Trial Design: One (More) Missed Opportunity. Journal of Clinical Oncology, 2020, 38, 649-651.	1.6	2
154	Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis. European Urology Open Science, 2020, 21, 61-68.	0.4	2
155	ASO Author Reflections: Palliative Chemotherapy for Upper Gastrointestinal Cancer: Balancing Hope, Reality, Survival, and Symptoms. Annals of Surgical Oncology, 2021, 28, 88-89.	1.5	2
156	Mental Health Resource Use Among Patients Undergoing Curative Intent Treatment for Bladder Cancer. Journal of the National Cancer Institute, 2021, 113, 1238-1245.	6.3	2
157	The association of gender and persistent opioid use following an acute pain event: A retrospective population based study of renal colic. PLoS ONE, 2021, 16, e0256582.	2.5	2
158	Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity—Reply. JAMA Oncology, 2021, 7, 1579.	7.1	2
159	No Outcome Differences after Cystectomy between Patients with De Novo Muscle-Invasive Bladder Cancer Compared to Progressors: A Retrospective Population-Based Study. Journal of Urology, 2021, 206, 260-269.	0.4	2
160	Palliative Radiotherapy for Esophageal and Gastric Cancer: Population-Based Patterns of Utilization and Outcomes in Ontario, Canada. Journal of Palliative Care, 2023, 38, 157-166.	1.0	2
161	Rising Healthcare Costs and Utilization among Young Adults with Cirrhosis in Ontario: A Population-Based Study. Canadian Journal of Gastroenterology and Hepatology, 2022, 2022, 1-13.	1.9	2
162	Colorectal Cancer Treatment Characteristics and Concordance With Guidelines in Sri Lanka: Results From a Hospital-Based Cancer Registry. JCO Global Oncology, 2022, , .	1.8	2

#	ARTICLE	IF	CITATIONS
163	Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey. JCO Global Oncology, 2022, , .	1.8	2
164	Optimizing care and outcomes of patients with muscle-invasive bladder cancer. Canadian Urological Association Journal, 2013, 7, 625.	0.6	1
165	The Role of Population-Based Observational Research in Bladder Cancer. Bladder Cancer, 2015, 1, 123-131.	0.4	1
166	Perioperative chemotherapy for bladder cancer: A qualitative study of physician knowledge, attitudes, and behaviour. Canadian Urological Association Journal, 2017, 12, E182-90.	0.6	1
167	What really matters at the end: perspectives from a patient, a family member and an oncologist. Cmaj, 2018, 190, E473-E475.	2.0	1
168	The role of sex in the outcomes of patients with biliary tract cancers remains unclear: A population-based study. American Journal of Surgery, 2018, 216, 1118-1121.	1.8	1
169	Do not use robotic surgery in oncology patients when conventional surgical approaches are equally effective “ Authors' reply. Lancet Oncology, The, 2019, 20, e241.	10.7	1
170	Leveraging High-Quality Research to Define the Gastric Cancer Landscape in India. Indian Journal of Surgical Oncology, 2020, 11, 334-336.	0.7	1
171	Statistical significance and clinical evidence “ Authors' reply. Lancet Oncology, The, 2020, 21, e119.	10.7	1
172	Application of Value Frameworks to the Design of Clinical Trials: The Canadian Cancer Trials Group Experience. Journal of the National Cancer Institute, 2021, 113, 1422-1428.	6.3	1
173	Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials. Current Oncology, 2021, 28, 1518-1527.	2.2	1
174	Tracking the Workforce 2020-2030: Making the Case for a Cancer Workforce Registry. JCO Global Oncology, 2021, 7, 925-933.	1.8	1
175	Practicing on the edge of oncology: when standard of care feels uncomfortable. Nature Reviews Clinical Oncology, 2021, 18, 673-674.	27.6	1
176	A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209.. Journal of Clinical Oncology, 2017, 35, 5021-5021.	1.6	1
177	Reliability of administrative data for evaluating the quality of systemic treatment for cancer.. Journal of Clinical Oncology, 2017, 35, 208-208.	1.6	1
178	Healthcare delivery for non-communicable diseases among breast cancer survivors in Sri Lanka: Is there a missed opportunity?. Ecancermedicalscience, 2021, 15, 1301.	1.1	1
179	Perioperative chemotherapy for muscle-invasive bladder cancer: Closing the gap between evidence and practice. Canadian Urological Association Journal, 2016, 10, 31.	0.6	1
180	Targeting the value of targeted therapy. Oncotarget, 2017, 8, 90612-90613.	1.8	1

#	ARTICLE	IF	CITATIONS
181	Radiographic progression-free survival in the ACIS trial for prostate cancer. <i>Lancet Oncology</i> , The, 2022, 23, e4.	10.7	1
182	Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity. <i>Current Oncology</i> , 2022, 29, 2530-2538.	2.2	1
183	Reply. <i>Urology</i> , 2014, 84, 1056-1057.	1.0	0
184	Toward affordable cancer drugs: Do we need firmer price negotiation, me-too drugs, or a biosimilar silver bullet?. <i>Seminars in Oncology</i> , 2020, 47, 353-354.	2.2	0
185	Choosing Wisely for Cancer Care in India. <i>Indian Journal of Surgery</i> , 2020, 82, 6-8.	0.3	0
186	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 268-269.	0.4	0
187	Achieving the achievable in muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2012, 6, 251-252.	0.6	0
188	Prognosis, treatment benefit, and goals of care: what do oncologists discuss with patients who have terminal cancer?. <i>Journal of Clinical Oncology</i> , 2015, 33, e20509-e20509.	1.6	0
189	Identifying opportunities to improve quality of cancer care: An evaluation of the use of diagnostic imaging in women curatively treated for early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6603-6603.	1.6	0
190	Adjuvant chemotherapy for stage II colon cancer: Practice patterns and effectiveness in the general population.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6569-6569.	1.6	0
191	Establishing achievable benchmarks for quality improvement in systemic therapy for early stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6591-6591.	1.6	0
192	Reasons for delay in time to initiation of adjuvant chemotherapy (TTAC) for colon cancer (CC): Analysis from six academic centers in Ontario, Canada.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6541-6541.	1.6	0
193	Chemotherapy delivery for resected colorectal cancer liver metastases: Management and outcomes in routine clinical practice.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18089-e18089.	1.6	0
194	Effects of a structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3621-3621.	1.6	0
195	Chemotherapy for resected colorectal cancer pulmonary metastases: Utilization and outcomes in routine clinical practice.. <i>Journal of Clinical Oncology</i> , 2017, 35, 236-236.	1.6	0
196	Uptake and effectiveness of FOLFIRINOX for advanced pancreas cancer: A population-based study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 245-245.	1.6	0
197	Prognostic impact of tumour laterality in early-stage colon cancer: A population-based study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15148-e15148.	1.6	0
198	Estimating the optimal rate of adjuvant chemotherapy utilization in stage III colon cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6591-6591.	1.6	0

#	ARTICLE	IF	CITATIONS
199	“Choosing Wisely” for cancer care in India. <i>Journal of Cancer Research and Therapeutics</i> , 2020, 16, 955.	0.9	0
200	“Choosing Wisely” for Cancer Care in India. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 567-569.	0.2	0
201	Contemporary clinical trials in hematologic cancer: Have we forgotten where we came from?. <i>European Journal of Cancer</i> , 2022, , .	2.8	0
202	ASO Visual Abstract: Incidence, Timing, and Outcomes of Venous Thromboembolism in Patients Undergoing Surgery for Esophagogastric Cancer: A Population-Based Cohort Study. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0